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Abstract 
 
Purpose of review: cardiac magnetic resonance (CMR) has emerged in recent years as a reliable 
tool to assess, in a single examination after a reperfused myocardial infarction, the initially area at 
risk (AAR), the final infarct size (IS) and from their difference the salvaged myocardium (SM). The 
aim of the present review is to summarize recent advances in the CMR imaging of SM. 
 
Recent findings: while there is consensus on the use of late gadolinium enhancement (LGE) to 
calculate IS, how to assess the AAR is a debated topic. The use of T2 weighted short-TI inversion 
recovery (T2W-STIR) is to date supported by a large amount of data, but it is affected by several 
limitations. Newer techniques have been developed to overcome T2W-STIR limitations, some of 
them have been already used in randomized clinical trials (RCTs) while others are showing 
promising results. The use of CMR to generate surrogate endpoints in RCTs is gaining attention; in 
this context, analyses of data from recent RCTs suggests that the assessment of SM as outcome 
measure could be useful to reduce sample sizes and costs of trials. 
 
Summary: CMR is a reliable technique for the assessment of SM. LGE is the gold standard for IS 
measurement, while which is the best technique for the evaluation of AAR is still debated. When 
using CMR-derived endpoints in RCTs, the assessment of SM is advisable. 
 
Keywords: Cardiac Magnetic Resonance; Myocardial Infarction; Area at Risk; Infarct Size; 
Salvaged Myocardium; Clinical Trials. 
  
Introduction 
The complete occlusion of a coronary artery initially generates a reversible myocardial injury 
within the vascular bed supplied by the occluded vessel. Subsequently, a necrotic injury starts to 
develop from the subendocardial layer, reaching within hours the epicardial layer in what has been 
called the “wavefront phenomenon” [1]. A prompt reperfusion interrupts the progression of the 
necrotic wavefront, leading to a salvage of a certain amount of myocardium that is ischemic but still 
not necrotic [2]. Since in the absence of an external intervention these cardiomyocytes would have 
been reached by the spreading of the necrosis, they have been referred to as salvaged myocardium 
(SM), while the initially ischemic area, as area-at-risk (AAR). The visualization of SM offers the 
opportunity to gain an insight into the mechanisms of myocardial damage after ischemia and 
reperfusion. By the histologic measurement of SM in animal models it was possible to identify 
several factors related to the spreading of the necrosis [2, 3, 4], acquiring information that had an 
impact on clinical practice. In vivo, several imaging techniques have been developed for the SM 
assessment, all of them relying on the assessment of the AAR and final infarct size (IS), while SM 
is obtained by their difference [5, 6]. Coronary angiography can be used to detect the AAR only, 
whereas echocardiography and cardiac computed tomography are less used for this purpose due to 
their inherent limitations (i.e. lack of validation, low sensibility and specificity, radiation exposure) 
[5]; on the other hand, single photon emission tomography (SPECT) and cardiac magnetic 
resonance (CMR) have been considered among the reference techniques [5]. However, although 
SPECT during the acute phase can be used to identify the AAR, this would require the injection of 
the tracer when the artery is still occluded, while the image acquisition takes place up to 8 hours 
after reperfusion and reflects the state of coronary perfusion before the intervention [7, 8]. The same 
exam should be repeated days later to detect the IS [9, 10]. The added value of CMR compared to 
SPECT is not only its ability to image the ischemic myocardium with a higher spatial resolution, 
but also the possibility to assess both AAR and IS retrospectively in a single examination [11]. 
Using CMR it was possible to directly assess in humans how different factors can impact the 
progression of the necrotic wave. In example, it was demonstrated how the duration of coronary 
occlusion possibly is one of the strongest determinants of SM [12]. Also, it has been previously 
shown that the presence of prodromal angina [13], female sex [14] and a lower heart rate at 
presentation [15] are all factors associated to a higher SM. Thanks to its reliability, CMR derived 
SM has been used as outcome measure in studies testing the effectiveness of new drugs or 
reperfusion strategies aiming to reduce the cardiomyocytes loss after an acute myocardial infarction 
[16 ••]. The present review will discuss recent advances and future perspectives in the CMR 
imaging of SM, with a focus on the different methods for SM imaging and on the use of SM as an 
end-point in clinical trials. 
Measuring Area at Risk 
The AAR is substantially the vascular bed of the occluded artery, a region initially subjected 
to a reversible ischemic injury that gradually becomes necrotic in the absence of any treatment. The 
use of CMR for the assessment of AAR has animated intense debates [17, 18]. T2 based techniques 
are the most widely used methods for the assessment of AAR in vivo, all of them essentially relying 
on the augmented water content within the ischemic myocardium [19, 20]. It was argued that limits 
of validation studies and pathophysiologic findings may suggest that imaging of edema does not 
truly depicts the ischemic myocardium [17]. Nevertheless, whatever the exact functional and 
anatomical abnormalities depicted by the CMR imaging of AAR are, it should be finally 
highlighted that in this context CMR has been successfully tested in the clinical arena. Specifically, 
SM with T2W-STIR derived AAR quantification has been validated against SPECT [21]. It showed 
good correlation with microsphere-evaluated AAR in an animal model [19], was proven to have 
prognostic relevance [22] and has been successfully used as an outcome measure in randomized 
controlled trials (RCTs) [16 ••]. 
The following paragraphs will focus on those CMR techniques for AAR quantification already used 
in the setting of RCTs. Description of the older or new but promising techniques will also be 
provided (Table 1). 
T2W-STIR. AAR is depicted by a bright signal when using T2 weighted short-TI inversion 
recovery sequence (T2W-STIR) [11]. The ischemia and subsequent reperfusion generates an 
inflammatory and edematous reaction that involves mostly the necrotic region, but also the peri-
infarct zone. Consequently, it was demonstrated that the bright images obtained by T2W-STIR 
reflect the edematous myocardial tissue and thus both the area of reversible and irreversible injury 
[23]. T2W-STIR was among the first used CMR techniques for the quantification of AAR [19] and 
a large amount of literature has been published so far. The presence of edema by T2W-STIR in the 
first days after an acute coronary syndrome was able to predict mortality [24] and also the extent of 
SM provided prognostic information, predicting mortality and major acute cardiovascular events in 
studies in which T2W-STIR was used to quantify the AAR [22, 25, 26]. Consequently, in the great 
majority of RCTs in which SM is used as an outcome measure, AAR assessment is carried out by 
the use of T2W-STIR (Appendix 1 and Supplementary Table 2).  However, the technique has many 
limitations. T2W-STIR imaging of the AAR is characterized by a low contrast between diseased 
and normal regions [17]. As a result, when compared with other techniques, T2W-STIR is affected 
by a higher interobserver variability [27 •]. Moreover, motion artifacts and slow-flow artifacts [28] 
can affect the quality of the images and prevent an appropriate interpretation of data. This 
eventuality ranges from only 5% of the examinations when considering a single center with high 
expertise [27], rising to 40% when analyzing multicenter data from RCTs [29]. This issue should be 
taken into account when measuring AAR with T2W-STIR. Another controversial point is which 
method should be used to measure the bright edematous area depicted by T2W-STIR. The 2 
standard deviation (2SD) method has been initially suggested [11]. However, different techniques 
have been used both in validation studies (i.e. 2SD [30] and manual contouring [21]) and in RCTs 
(see Supplementary Table 2). In this context, a recent research found that manual contouring 
provides the lowest variability (intraobserver, interobserver and interscan) when compared to 6 
other methods [31 •]. However, it should be highlighted that this study was carried out in a single 
center with a high expertise in the technique. 
T2 mapping. Assessment of the AAR can also be carried out using T2 mapping. This recently 
developed technique uses T2-prepared steady state free precession sequences to enable a 
quantitative detection of edema, overcoming some of the T2W-STIR related limitations [32]. T2 
mapping has been validated in an animal model against the microsphere evaluated AAR [33]. In 
vivo, it was compared with SPECT, showing good agreement with the extent of AAR as determined 
by nuclear imaging with a grade of correlation comparable to T1 mapping and possibly better than 
T2W-STIR [34]. When compared to T2W-STIR, T2 mapping enables the acquisition of images 
with a higher diagnostic quality and the detection of the AAR with a higher sensibility [35]. This 
technique was also proven to be the most reproducible method for the assessment of the AAR and it 
was described as a less user-dependent technique with a smaller learning curve [27 •]. For these 
reasons, T2 mapping is emerging as a robust technique for the quantification of AAR. It has been 
used as reference technique in studies that tested newer CMR sequences for the evaluation of AAR 
[36 ••] and also for AAR quantification in RCTs that used SM as outcome measure [37]. However, 
data on prognosis are still lacking. 
CE-SSFP. Contrast-enhanced steady-state free precession (CE-SSFP) generates images that are 
dependent on T2/T1 ratio [38] and can be used to visualize the AAR that appears brighter than the 
remote myocardium [39]. The reasons of this phenomenon are not completely understood. During a 
myocardial infarction, an increased distribution volume takes place also in reversibly injured 
myocardium [40, 41] and this would probably affect also the distribution of gadolinium contrast 
media, leading to an increased signal within the AAR [42]. CE-SSFP for the imaging of AAR has 
been validated against SPECT [39] and performed well when compared to T2W-STIR [42]. More 
recently, CE-SSFP was used to quantify AAR and calculate SM in 2 large RCTs [43, 44]. Analyses 
of data from these 2 trials showed that CE-SSFP had a good agreement with T2W-STIR in the 
quantification of AAR and in the identification of the culprit artery. Interestingly, a lower number 
of exams had a non-diagnostic value with CE-SSFP (6%) rather than with T2W-STIR (40%) [29]. 
CE-SSFP for the imaging of AAR is a more recent technique than T2W-STIR, thus less data is 
available (i.e. prediction of prognosis). Moreover, a comparison with newer techniques such as T2 
mapping and T1 mapping is missing. 
Other techniques. Among other techniques available for the assessment of the AAR, T1 mapping 
by the use of modified look-locker inversion recovery (MOLLI) sequences has emerged as one of 
the most promising both in animal models [33] and in vivo [45]. It was validated against SPECT, 
performing well when compared to data provided by the nuclear imaging [34].  AAR quantification 
by T1 mapping has been validated also against T2 mapping, showing a very high correlation [45]. 
Notably, it was proposed that using native and post-contrast T1 mapping it would be possible to 
delineate both the AAR and the IS, thus shortening the duration of the CMR examination [46]. In a 
recent study, pre- and post-contrast acquisition and hematocrit level were utilized to describe 
extracellular volume maps; through them it could be possible to differentiate the AAR and IS from 
the remote myocardium and to calculate SM [47 •]. Even more attractive is the observation that 
using different thresholds it is possible to assess both AAR and IS by the use of native T1 mapping 
only, without the need of contrast media administration [36 ••]; in this case, T1 maps also provided 
prognostic information, predicting a worse left ventricular ejection fraction and wall-thickening at a 
6-month follow-up [36 ••]. Further studies are needed to extend and confirm these recent 
observations. 
The early gadolinium enhancement (EGE) technique requires the acquisition of images early (2 
minutes) after the injection of the gadolinium based contrast media. This allows to observe an area 
of hyperenhancement in the vascular bed of the occluded artery. The enhanced area is transmural, 
bigger than the final IS and it corresponds to the extent of AAR as determined by T2W-STIR [48]. 
A limitation to the use of EGE for the assessment of AAR is due to the high variability in relation to 
small changes in time of acquisition. This leads to a higher variability when compared to other 
techniques [31 •]. 
Bright-blood T2-weighted sequences (Acquisition for Cardiac Unified T2 Edema, ACUT2E) render 
images with a hybrid combination of T1 and T2 components [49]. It performed sufficiently well 
when compared to other techniques for AAR quantification [31 •] but it did not gain widespread 
use. 
The method of the endocardial surface area (ESA) is based on the pathophysiologic assumption of 
the wavefront phenomenon [1, 2]. Since endocardial extension of the necrotic area is defined within 
40 minutes after the coronary occlusion, the ESA method assumes that the extent of the necrotic 
endocardial surface, expressed as a percentage of the total left ventricular endocardial surface, 
reflects the AAR. An advantage of ESA method is the possibility to calculate the AAR with only 
one sequence (late gadolinium enhancement, LGE). However, even if it performed well against 
other techniques for AAR measurement [50], several limitations have been pointed out, including 
the risk of underestimating AAR, and subsequently SM, in patients with a small IS or with aborted 
infarction [51]. 
In summary, there is presently no clear consensus on how to measure the AAR by means of 
CMR. Based on the published data, it seems that the use of T2W-STIR with manual contouring, in 
centers with a high expertise on the technique, could reliably depict the ischemic myocardium with 
an acceptable rate of images with diagnostic quality. It should be also highlighted that AAR and SM 
quantification by means of T2W-STIR rely on a vast amount of literature data and can provide 
prognostic information. On the other hand, several limitations to this technique have been pointed 
out, and in the context of RCTs both the results variability and the optimal quality of acquired 
imaging in all centers are of major importance. T2 mapping and CE-SSFP seem able to overcome 
some of the T2W-STIR limitations and they have been both successfully used in multicenter 
clinical trials. Furthermore, T2 mapping has been used as reference technique in studies validating 
new CMR sequences for AAR evaluation. Several other techniques are currently being tested, 
among them, T1 mapping appears promising. Future studies should comprehensively investigate the 
prognostic value of these more recent mapping techniques and their inherent limitations. In 
example, parametric relaxation parameters may significantly vary in relation to the machine and 
protocol used. Thus, normal and abnormal value ranges have not been clearly identified yet. 
Measuring Infarct size 
The necrotic area that results after a myocardial infarction is very well depicted by CMR [ 52, 53, 
54, 55]. When administered in the few days after a myocardial infarction, gadolinium based contrast 
media enters in the irreversibly injured cells due to the cell membrane rupture [53]. This causes a 
reduced late wash-out and so the presence of a late enhancement (LGE). Conversely, in the chronic 
phase the contrast media accumulates in the collagen rich interstitium of the myocardial scar, 
causing an area of LGE that is usually smaller than the one measured in the acute phase [56]. Even 
if LGE images can provide a measure of the extent of necrosis both in the acute and chronic phase, 
the extent of LGE in the acute phase should be taken into account when evaluating SM. In fact, this 
is the measure that was proven to have prognostic relevance [22, 25, 26]. Native T1 mapping has 
been recently proposed as a technique to quantify myocardial necrosis and to overcome some of the 
critical points related to LGE imaging (i.e. image acquisition timing, post-processing and 
measurement method) [36 •], however LGE remains a robust parameter with a large amount of 
published data especially on prognosis after myocardial infarction [57], and is currently considered 
as the gold standard to quantify IS [58]. 
Limits of LGE measurement in the context of randomized clinical trials have been pointed out in a 
recent meta-analysis investigating 62 studies in which LGE was used as an outcome measure [59 •]. 
It was found that 3 different gadolinium based contrast media were used, and that this information 
was provided only by 69% of the pooled trials; measurement of the late enhancement area was 
carried out by 7 different methods, but this information was not included in the 27% of the studies. 
Moreover, data about timing of the CMR examination were not always provided nor were 
completely uniform among the different studies. Despite all these limitations, the authors were able 
to propose a sample size calculation based on the IS extent in the control arms; however, they also 
addressed the need for a protocol standardization in order to allow an easier and more accurate 
comparison between different trials. In relation to this issue, it was shown that the measurement of 
LGE in the first days after a myocardial infarction has the lowest variability (intraobserver, 
interobserver and interscan) if carried out by manual contouring (performed in expert hands) when 
compared with 6 other techniques [31 •].  
Measuring myocardial salvage 
The extent of SM is given by the difference between the extent of AAR and IS. Because both are 
not constant after an acute myocardial infarction, the right timing to perform a CMR examination 
for SM assessment is a discussed topic. It was proposed that the first week after the acute event may 
represent an optimal and stable window for AAR evaluation [56]. Conversely, other authors 
hypothesized that a bimodal trend of edema is present and should be taken into account in this time 
period [58]; however, this hypothesis is debated and a recent large study suggested the presence of a 
unimodal trend of edema [61]. IS as determined by LGE decreases over time after a myocardial 
infarction [56]. Thus, especially in the context of a clinical trial, it is important that no significantly 
difference in scan day are found between groups (i.e. control and treatment arms) even considering 
the first week after the acute event [16 ••]. 
Recent data suggests that using quantitative techniques such as T1 mapping [36] and T2 mapping 
[62] it could be possible to discriminate between AAR, IS and remote myocardium by the use of 
different cut off values within the same parametric image. Further studies are needed to address this 
point and extend these results. 
Myocardial salvage as endpoint in clinical trials 
A surrogate end-point (SEP) is a laboratory or physiological marker used in substitution of a 
clinical end-point in RCTs. The use of a SEP enables to reduce sample size, duration and cost of a 
trial [63, 64]. Using CMR it is possible to assess several valid SEP, such as IS, SM and 
microvascular obstruction [64]. Among them, IS extent as assessed by LGE-CMR is one of the best 
measure for event prediction after a myocardial infarction [65]. Thus, it has been widely used as a 
SEP in clinical cardioprotection trials [59 •]. However, the use of IS in this setting carries several 
limitations to the evaluation of the truly effectiveness of a tested treatment. In fact, IS extent largely 
depends on factors not related to the treatment, such as the extent of AAR [66] that in turn is related 
to the extent of the occluded artery vascular bed [67]. In example, an individual with an extensive 
anterior myocardial infarction, even if treated with an early reperfusion, would have a larger AAR 
and IS when compared to a patient with a late reperfusion of a small right coronary artery. 
However, in the first case SM would be greater, since the early reperfusion makes possible for a 
larger part of the AAR to be spared by the necrosis: taking into account IS extent only in such a 
patient would not have helped in demonstrating the usefulness of the treatment. The extent of AAR 
and IS is related to the site of the coronary occlusion, while the extent of SM is not [15, 68]. This 
has important implications when projecting clinical trials in which IS is used as surrogate end-point. 
Moreover, to provide a balanced distribution of myocardial infarction locations between the study 
groups (i.e. anterior vs non-anterior myocardial infarction) it might not be enough to eliminate the 
discrepancies caused by differences in AAR extent. In fact, even considering only patients with an 
occlusion of the left anterior descending artery, the area of reversible injury may significantly vary 
according to the precise location of the occlusion (i.e. proximal vs mid) or the anatomy (i.e. number 
and size of side branches) of different individuals, as shown by angiographic risk scores of AAR 
prediction [69]. However, it should be highlighted that if the analyzed factor or tested treatment has 
a large impact on SM (i.e. time to reperfusion), all confounding factors can be overcome and a 
reduction in IS can be observed [12]. On the other hand, it may happen that the impact of the 
analyzed factor is lower, there are significant anatomical differences between groups or the sample 
size is too small. In this case, the assessment of IS alone does not reveal an effect of the tested 
factor or treatment that actually exists (type 2 error), while an improvement of SM is still observed 
[15, 70]. Augmentation of sample size could be useful to overcome confounding factors related to 
the use of IS as outcome measure. However, in this context SM appears to be a more sensitive 
marker to evaluate the effectiveness of new reperfusion strategies, thus, its use could help to reduce 
sample sizes and costs in clinical trials, as recently demonstrated [16 ••]. A list of the main 
published cardioprotection trials that used SM as outcome measure is reported in the Appendix 1 
and Supplementary Table 2. Some limitations inherent the use of SM as endpoint in clinical trials 
should be mentioned. First, to measure SM it is necessary to assess both the AAR and IS, but the 
evaluation of AAR is field of several debates, as mentioned before. The assessment of AAR largely 
relies on the edema that characterize the ischemic area, however, some tested treatments may also 
reduce the extent of edema, leading to an underestimation of the SM in the treated arm [34]. In 
conclusion, the assessment of SM owns presently the properties of a valid SEP, even if some 
limitations should be taken into account. When using CMR to assess SEPs in clinical trials, the 
measurement of SM (along with others imaging parameters) is advisable. 
Conclusions 
CMR is a reliable technique for the assessment of SM. LGE is the gold standard for the assessment 
of IS, while which is the best technique for the assessment of AAR is still debated. Increasing data 
are present in literature on CMR used as a method for the quantification of SEPs in clinical trials. In 
this case, both from a pathophysiologic and a practical point of view, the assessment of SM as 
outcome measure is advisable. 
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